What did @daviddemesquita actually say?
The creator's core argument is that MK-677 looks good on paper but underdelivers on its main promise. He says it produces a short-term spike in growth hormone that "has a very long half-life," but after roughly 30 days, levels return to baseline, sometimes dropping below it. He also calls it a "gremlin agonist" (ghrelin), notes it reliably increases appetite, and flags insulin resistance and blood pressure increases as side effects. His bottom line: MK-677 is more useful as an appetite driver than a legitimate growth hormone tool.
That's a more honest take than most MK-677 content on this platform, which tends to oversell it as injectable HGH's oral cousin. He's working with real concepts, even if the execution has some rough edges.
Does the science back this up?
Partially, yes. The short-term GH spike is real and well-documented. The 30-day attenuation claim is also supported. The side effect profile is accurate. But the half-life framing is confused, and the causal explanation for blood pressure is not well established in the literature.
Nass et al. (1999, Journal of Clinical Endocrinology and Metabolism) showed that MK-677 significantly elevated GH and IGF-1 in healthy older adults over two years, but GH pulse amplitude declined over time even as IGF-1 remained elevated. A separate study by Murphy et al. (1998, Journal of Clinical Endocrinology and Metabolism) confirmed acute GH secretion stimulation but noted blunting with continued use. The appetite effect through ghrelin receptor agonism is well established. Chapman et al. (1996, Journal of Clinical Endocrinology and Metabolism) documented both the GH secretory effect and appetite stimulation in early trials. Insulin resistance as a side effect is documented across multiple trials, likely related to elevated GH and IGF-1 signaling rather than a vague "inflammatory response," which is how the creator frames it.
What did they get wrong or right?
The biggest factual error is the half-life claim. He says the growth hormone releasing has "a very long half-life," which appears to confuse the half-life of MK-677 itself (roughly 24 hours, which is genuinely long for a secretagogue) with the half-life of the GH pulses it generates. GH itself has a short half-life of about 20-30 minutes. Conflating these is a meaningful error that could mislead viewers about how and why the compound works.
The "inflammatory response" explanation for blood pressure and insulin resistance is also vague and not well supported. Insulin resistance in this context is more plausibly driven by the counter-regulatory effects of elevated GH on insulin sensitivity, a known physiological mechanism, not a generic inflammatory pathway. Calling the ghrelin receptor a "gremlin" receptor twice is just a verbal slip, not a factual error, but it may confuse viewers who don't know the term.
What he got right: the attenuation of GH response over time, the appetite effect being reliable and clinically meaningful, and the overall skeptical framing. The honest admission that it "doesn't work well" for GH is more accurate than most fitness content on this compound.
What should you actually know?
MK-677 is an orally active ghrelin receptor agonist. It is not a peptide in the traditional sense and is not FDA-approved for any indication. It is being studied, but the research base is thinner than its popularity on social media would suggest.
The IGF-1 elevation is real and sustained in some studies even after GH pulse attenuation, which is worth knowing separately. But elevated IGF-1 over long periods is not consequence-free, and anyone considering this compound should have that conversation with a licensed provider who can monitor relevant biomarkers. The insulin resistance signal is consistent across the literature and should not be dismissed as a minor inconvenience, particularly for people with metabolic risk factors. Huang et al. (2020, Frontiers in Endocrinology) reviewed the metabolic trade-offs and concluded the risk-benefit calculation for healthy adults is not straightforward. If you are looking at MK-677 primarily to eat more, there are better-studied and lower-risk ways to address appetite. If you are looking at it for GH optimization, the data suggest diminishing returns fairly quickly.